M
Malcolm F. G. Stevens
Researcher at University of Nottingham
Publications - 316
Citations - 13044
Malcolm F. G. Stevens is an academic researcher from University of Nottingham. The author has contributed to research in topics: Temozolomide & Benzothiazole. The author has an hindex of 57, co-authored 315 publications receiving 12291 citations. Previous affiliations of Malcolm F. G. Stevens include Keele University & Hauptman-Woodward Medical Research Institute.
Papers
More filters
Journal ArticleDOI
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials
Edward S. Newlands,Malcolm F. G. Stevens,Stephen R. Wedge,Richard T. Wheelhouse,Cathryn S Brock +4 more
TL;DR: This poster presents a poster presented at the 2016 American Academy of Medical Oncology Congress on Wednesday, 3 March 2016 calling for awareness of the importance of informed consent in the selection of patients for cancer treatment.
Journal ArticleDOI
Temozolomide: Mechanisms of Action, Repair and Resistance
TL;DR: Several small molecule inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1), a critical BER protein are yielding promising results clinically, both in combination with TMZ and as single agent chemotherapy in patients whose tumours possess homologous recombination DNA repair defects.
Journal ArticleDOI
Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).
Edward S. Newlands,George Blackledge,J. A. Slack,Gordon J. S. Rustin,D. B. Smith,N. S. A. Stuart,C. P. Quarterman,R. Hoffman,Malcolm F. G. Stevens,M. H. Brampton +9 more
TL;DR: In the extended Phase I trial temozolomide only occasionally exhibited the unpredictable myelosuppression seen with mitozolmide, which is easy to use clinically and generally well tolerated.
Journal ArticleDOI
Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines.
Catriona G. Mortimer,Geoffrey Wells,Jean-Philippe Crochard,Erica L. Stone,Tracey D. Bradshaw,Malcolm F. G. Stevens,Andrew D. Westwell +6 more
TL;DR: Mechanistically, this new series of agents contrasts with the previously reported 2-(4-aminophenyl)benzothiazoles; compound 8n is not reliant on induction of CYP1A1 expression for antitumor activity.
Journal Article
Antitumor Activity and Pharmacokinetics in Mice of 8-Carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a Novel Drug with Potential as an Alternative to Dacarbazine
Malcolm F. G. Stevens,John A. Hickman,Simon P. Langdon,David Chubb,Lisa M. Vickers,Robert Stone,Ghousia Baig,Colin Goddard,Neil W. Gibson,John Alfred Slack,Christopher Newton,Edward Lunt,Christian Fizames,François Lavelle +13 more
TL;DR: The 3-methyl analogue, 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045), was investigated further and found to possess good activity, when administered i.p. or p.o. to mice bearing the L1210 leukemia.